MAIA Biotechnology, Inc. (MAIA) News
Follow MAIA Biotechnology, Inc. (MAIA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE: MAIA ) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment mile
LIVE | Oct 07, 2026, 12:16 PM UTC
L
MAIA Biotechnology (MAIA) Expands Phase 3 THIO-104 Trial to Spain and Portugal
MAIA Biotechnology received approvals in Spain and Portugal to begin screening for its pivotal Phase 3 THIO-104 NSCLC trial, targeting ~100 patients dosed by year-end 2026 and an interim survival analysis expected in 202
NEWS | Sep 23, 2026, 01:23 PM UTC
L
MAIA - MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
MAIA - MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
NEWS | Sep 23, 2026, 01:17 PM UTC
L
MAIA - MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
MAIA - MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
NEWS | Sep 22, 2026, 12:52 PM UTC
L
MAIA - MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
MAIA - MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
NEWS | Sep 16, 2026, 12:22 PM UTC
L
MAIA Biotechnology, Inc. (AMEX:MAIA) Discloses Insider Share Purchases
Board member Ramiro Guerrero bought 185,078 shares for about $252,284 at $1.36 avg. CEO Vlad Vitoc bought 73,000 shares at $1.37 avg. Directors and officers now hold 21.34% as of Sept. 14, 2026.Material DetailsContext by
EQUITY | Sep 15, 2026, 12:21 PM UTC
L
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today annou
EQUITY | Sep 15, 2026, 12:15 PM UTC
L
MAIA - MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
MAIA - MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
EQUITY | Sep 10, 2026, 12:15 PM UTC
L
MAIA files $150 million mixed shelf registration
MAIA files a Form S-3 for a $150,000,000 mixed shelf registration, allowing it to issue or sell securities under the shelf statement.
REGULATION | Aug 21, 2026, 08:17 PM UTC
M
MAIA files to offer securities up to $150 million
MAIA files an SEC registration indicating it may offer securities up to $150 million, with no catalyst or timing detail supplied in the alert.
MNA | Aug 21, 2026, 08:16 PM UTC
L
MAIA Completes Enrollment
MAIA Biotechnology completes international enrollment in Part C of Phase 2 THIO-101 expansion trial in third-line non-small cell lung cancer
EQUITY | Jun 25, 2026, 12:08 PM UTC